UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

 

 

FORM 8-K

 

CURRENT REPORT

Pursuant to Section 13 or 15(d)

of the Securities Exchange Act of 1934.

Date of Report: November 28, 2018

(Date of earliest event reported)

 

 
BioVie Inc.
(Exact name of registrant as specified in its charter) 

 

 

 

Nevada   000-55292   46-2510769

(State or other jurisdiction

of incorporation)

 

(Commission

File Number)

 

(IRS Employer

Identification Number)

   
11601 Wilshire Blvd., Suite 1100, Los Angeles, CA   90025
(Address of principal executive offices)   (Zip Code)

(312) 283-5793

(Registrant’s telephone number, including area code)

 

 

 

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:

 

¨ Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)

 

¨ Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)

 

¨ Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))

 

¨ Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

  

Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b–2 of this chapter).

Emerging growth company ☐

 

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐

 

 
 

Item 8.01 Other Events

On November 28, 2018, BioVie Inc. (“BioVie”) issued a press release announcing that the U.S. Food and Drug Administration had granted an Orphan Drug designation to Biovie for terlipressin for the treatment of hepatorenal syndrome. A copy of the press release is provided as Exhibit 99.1 to this Current Report.

 

Item 9.01 Exhibits

 

(d) Exhibits

 

Exhibit Number   Description
  99.1     Press Release of BioVie Inc. dated November 28, 2018

 

 

 - 1 -

 

SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

 

Dated: November 29, 2018       BIOVIE INC.  
         
        By:  

/ s/ Jonathan Adams

 
            Jonathan Adams  
            President & Chief Operating Officer  
   
     
                   

 

 - 2 -

 

EXHIBIT INDEX

Exhibit Number   Description
  99.1     Press Release of BioVie Inc. dated November 28, 2018

 

 - 3 -